VEGF120產(chǎn)品信息
英文名稱:Vascular endothelial growth factor A
中文名稱:血管內(nèi)皮生長(zhǎng)因子A
靶點(diǎn)別稱:VEGF120,VEGFA
物種:Mouse
標(biāo)簽:Tag Free/His Tag & Avi Tag
屬性:Protein
標(biāo)記:Biotin-labeled/Unconjugated
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Mouse VEGF120 Protein, Tag Free (VE0-M4211) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 146 (Accession # AAB22254.1 ).
Predicted N-terminus: Ala 27
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries no "tag".
The protein has a calculated MW of 14.1 kDa. The protein migrates as 18-22 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 0.1 EU per μg by the LAL method.
無(wú)菌(Sterility)
Negative
純度(Purity)
>95% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
血管內(nèi)皮生長(zhǎng)因子A(VEGFA)也稱為血管通透性因子(VPF)。VEGFA屬于PDGF/VEGF生長(zhǎng)因子家族。VEGFA是一種糖基化絲裂原,特異性作用于內(nèi)皮細(xì)胞,具有多種作用,包括介導(dǎo)血管通透性增加、誘導(dǎo)血管生成、血管生成和內(nèi)皮細(xì)胞生長(zhǎng)、促進(jìn)細(xì)胞遷移和抑制凋亡?;蛘?,編碼自由分泌或細(xì)胞相關(guān)異構(gòu)體的剪接轉(zhuǎn)錄變體已被表征。由于選擇性剪接,VEGFA由一組三種主要亞型產(chǎn)生,如果產(chǎn)生任何三種亞型(VEGFA120、VEGFA164和VEGFA188),則不會(huì)導(dǎo)致小鼠血管缺陷和完全VEGFA敲除死亡。
關(guān)鍵字: VEGFA;VEGFA蛋白;VEGF120重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。